Internal Medicine Alert – December 15, 2002
December 15, 2002
View Issues
-
A Modern Day Faustus: COX-2 Inhibitors — Are We Trading Gastric Protection for Cardiac Death?
This study suggests that high-dose rofecoxib may increase the risk of cardiovascular events. -
Valproate for Diabetic Painful Neuropathy
Sodium valproate appears safe and effective for the management of DPSN. -
Helicobacter pylori Infection
Helicobacter pylori is an exceedingly common inhabitant of the human stomach. The discovery of its role in the pathogenesis of peptic ulcer disease was revolutionary, but many questions remain about this organism and an appropriate medical approach to its presence. -
The Effect of the Amount and Intensity of Exercise on the Plasma Lipoproteins
There were widespread beneficial effects of high amounts of exercise on plasma lipoproteins. -
Pharmacology Update: Adefovir (Hepsera) for the Treatment of Chronic Hepatitis B Infection
The FDA has recently approved adefovir dipivoxil for the treatment of chronic hepatitis B in adults. This prodrug of adefovir is a nucleotide analog that was originally developed for the treatment of HIV infections but has also been found to be active against the hepatitis B virus. -
Clinical Briefs
Effects of Long-Term Treatment With ACE Inhibitors in the Presence or Absence of Aspirin; Long-Term Risks Associated with Atrial Fibrillation: 20-Year Follow-up of the Renfrew/Paisley Study; Olfactory Impairment in Older Adults -
ECG Review: What’s Going On? (Part II)
The 12-lead ECG and accompanying rhythm strip in the Figure were obtained from an 84-year-old man who presented to the Emergency Department with acute dyspnea from pneumonia and heart failure. Can you account for the relatively slow heart rate despite his acute shortness of breath? -
Pharmacology Watch: FDA Approves Generic Version of AstraZeneca’s Prilosec
The FDA has approved the first generic version of AstraZeneca plcs blockbuster drug, omeprazole (Prilosec).